Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
November 18, 2021 08:30 ET
|
Aerami Therapeutics
DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases,...
Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors
November 11, 2021 08:30 ET
|
Aerami Therapeutics
DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced...
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension
June 24, 2021 08:00 ET
|
Aerami Therapeutics
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifyingDosing of patients in Phase 1 trial is...
Aerami Therapeutics to Present at the LifeSci Partners Summer Symposium
July 23, 2020 08:00 ET
|
Aerami Therapeutics
DURHAM, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (the “Company”) announced today that Anne Whitaker, Chief Executive Officer, will present a corporate overview at the...
Aerami Therapeutics Signs a Global License Agreement with Vectura Group, Adding an Inhaled Therapy for Patients with Pulmonary Arterial Hypertension to Their Pipeline
June 08, 2020 08:15 ET
|
Aerami Therapeutics
DURHAM, N.C., June 08, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...
Aerami Therapeutics Appoints Timm Crowder as Chief Operating Officer
February 05, 2020 08:30 ET
|
Aerami Therapeutics
DURHAM, N.C., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Aerami Therapeutics, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced the appointment of...
Aerami Therapeutics to Present Clinical Data on Dance 501 Inhaled Human Insulin at the 19th Diabetes Technology Meeting
November 11, 2019 08:00 ET
|
Aerami Therapeutics
DURHAM, N.C., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Aerami Therapeutics, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced that it will...
Dance Biopharm Announces Rebranding to Aerami Therapeutics Reflecting a Broadened Strategic Focus on Inhaled Therapies for Chronic Diseases
September 25, 2019 07:30 ET
|
Aerami Therapeutics
Aerami is exploring inhaled therapies beyond human insulin in multiple chronic conditions Launched three new pipeline programs aimed at treatment of type 2 diabetes, hypoparathyroidism and human...
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin at European Association for the Study of Diabetes Meeting
September 19, 2019 08:30 ET
|
Dance Biopharm
Data demonstrated earlier onset of action and higher early effect of Dance 501 inhaled insulin compared to injected insulin lispro in patients with type 2 diabetes Validated smart inhaler delivers...